Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer.


Journal

Biochimica et biophysica acta. Reviews on cancer
ISSN: 1879-2561
Titre abrégé: Biochim Biophys Acta Rev Cancer
Pays: Netherlands
ID NLM: 9806362

Informations de publication

Date de publication:
04 2021
Historique:
received: 05 11 2020
revised: 30 12 2020
accepted: 02 01 2021
pubmed: 12 1 2021
medline: 20 7 2021
entrez: 11 1 2021
Statut: ppublish

Résumé

Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) is a widely studied lncRNA in cancer. Although dispensable for normal physiology, MALAT1 is important for cancer-related pathways regulation. It is localized in the nuclear speckles periphery along with centrally located pre-RNA splicing factors. MALAT1 associated cancer signaling pathways include MAPK/ERK, PI3K/AKT, β-catenin/Wnt, Hippo, VEGF, YAP, etc. Molecular tools such as immunoprecipitation, RNA pull-down, reporter assay, Northern blotting, microarray, and q-RT-PCR has been used to elucidate MALAT1's function in cancer pathogenesis. MALAT1 can regulate multiple steps in the development of tumours. The diagnostic and prognostic significance of MALAT1 has been demonstrated in cancers of the breast, cervix, colorectum, gallbladder, lung, ovary, pancreas, prostate, glioma, hepatocellular carcinoma, and multiple myeloma. MALAT1 has also emerged as a novel therapeutic target for solid as well as hematological malignancies. In experimental models, siRNA and antisense oligonucleotide (ASO) based strategy has been used for targeting MALAT1. The lncRNA has also been targeted for the chemosensitization and radiosensitization of cancer cells. However, most studies have been performed in preclinical models. How the cross-talk of MALAT1 with other signaling pathways affect cancer pathogenesis is the focus of this article. The diagnostic, prognostic, and therapeutic significance of MALAT1 in multiple cancer types are discussed.

Identifiants

pubmed: 33428963
pii: S0304-419X(21)00001-9
doi: 10.1016/j.bbcan.2021.188502
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
MALAT1 long non-coding RNA, human 0
RNA, Long Noncoding 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

188502

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Bela Goyal (B)

Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.

Shashi Ranjan Mani Yadav (SRM)

Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.

Nikee Awasthee (N)

Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, India.

Sweety Gupta (S)

Department of Radiation Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.

Ajaikumar B Kunnumakkara (AB)

Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, 781039, India.

Subash Chandra Gupta (SC)

Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, India. Electronic address: sgupta@bhu.ac.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH